T. Takemoto

发表

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

J. Soh, T. Mitsudomi, T. Koga, 2022, Journal of Hematology & Oncology.

Prognostic impact of pleural lavage cytology in patients with primary lung cancer.

T. Mitsudomi, S. Shimizu, Takao Sato, 2016, Lung cancer.

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC

J. Soh, T. Mitsudomi, T. Koga, 2022, JTO clinical and research reports.

KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from the in vitro experiments.

J. Soh, T. Mitsudomi, T. Arita, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Kenichi Suda, Masaki Shimoji, Toyoaki Hida, 2015, Clinical Cancer Research.

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.

T. Mitsudomi, T. Koga, Yoshihisa Kobayashi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.

J. Soh, T. Mitsudomi, T. Koga, 2021, Lung cancer.

Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas

J. Soh, T. Mitsudomi, S. Shimizu, 2019, Biomolecules.

Esophageal perforation caused by a fish bone treated with surgically indwelling drainage and fibrin glue injection for fistula formation.

H. Shiono, Toru Kimura, K. Yane, 2013, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.

T. Mitsudomi, S. Shimizu, Yoshihisa Kobayashi, 2017, Lung cancer.

A resected case of large-cell neuroendocrine carcinoma of the thymus

T. Mitsudomi, H. Mizuuchi, K. Suda, 2015 .

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

J. Soh, T. Mitsudomi, K. Nishio, 2020, Translational lung cancer research.

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.

P. Jänne, T. Mitsudomi, T. Kosaka, 2018, Lung cancer.

Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.

J. Soh, T. Mitsudomi, T. Koga, 2021, Lung cancer.

Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.

T. Mitsudomi, Yoshihisa Kobayashi, M. Chiba, 2017, Lung cancer.

The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor

Kenichi Suda, T. Mitsudomi, Tetsuya Mitsudomi, 2014, International journal of cancer.

CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.

Y. Yatabe, T. Mitsudomi, F. Tanaka, 2014, Lung cancer.

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer

T. Mitsudomi, Y. Sekido, K. Nishio, 2016, Cancer science.

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Young Hak Kim, T. Mitsudomi, K. Nishio, 2016, Molecular Cancer Therapeutics.

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

T. Mitsudomi, T. Koga, Yoshihisa Kobayashi, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery

J. Soh, T. Mitsudomi, T. Koga, 2021, Surgery Today.

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).

T. Mitsudomi, S. Shimizu, Yoshihisa Kobayashi, 2016, Lung cancer.

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.

T. Mitsudomi, T. Koga, Yoshihisa Kobayashi, 2018, Lung cancer.

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection

T. Mitsudomi, H. Kuwano, M. Sakaguchi, 2015, Thoracic cancer.

Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma

T. Mitsudomi, S. Shimizu, M. Sakaguchi, 2014, BioMed research international.

Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.

J. Soh, T. Mitsudomi, A. Hamada, 2021, Clinical lung cancer.